3 Docket No.: C0875.70019US02

Application No. 10/572,667 Amendment dated September 29, 2010 After Final Office Action of May 6, 2010

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims in this application with the following claims. Insertions are indicated by underlining and deletions are indicated by strikeouts or double bracketing.

- (Currently amended) A method for treating a subject having non-fungal induced mucositis
 of the distal intestinal tract, comprising administering locally to the distal intestinal tract of the
 subject an anti-fungal azole compound in an amount effective to reduce or eliminate the non-fungal
 induced mucositis of the distal intestinal tract, wherein the effective amount is <u>administered in a</u>
 single dosage in the range of 2,000 mg to 10,000 mg of the anti-fungal azole compound.
- (Currently amended) The method of claim 1, wherein the effective amount is administered in a single dosage at a frequency of administration from four times a day to once a month.
- 3. (Original) The method of claim 1, wherein the non-fungal induced mucositis of the distal intestinal tract is selected from the group consisting of pouchitis, ulcerative colitis, Crohn's disease, allergic colitis, autoimmune colitis, autoimmune enteropathy, bacterial colitis, diversion colitis and lymphocytic colitis.
- (Original) The method of claim 1, wherein the non-fungal induced mucositis of the distal intestinal tract is pouchitis.
- (Original) The method of claim 1, wherein the mucositis of the distal intestinal tract is nonmicrobial induced.
- 6. (Previously presented) The method of claim 1, wherein the effective amount is from 2,500 mg to 10,000 mg at a frequency of from twice a day to once every two weeks.
- 7. (Previously presented) The method of claim 1, wherein the subject is a human.

4 Docket No.: C0875,70019US02

Application No. 10/572,667 Amendment dated September 29, 2010 After Final Office Action of May 6, 2010

(Original) The method of claim 7, wherein the anti-fungal azole compound is selected from
the group consisting of anti-fungal imidazole compounds, anti-fungal triazole compounds and antifungal nitroimidazole compounds.

- (Original) The method of claim 8, wherein the anti-fungal azole compound is an antifungal imidazole compound.
- (Previously presented) The method of claim 9, wherein the anti-fungal imidazole compound is clotrimazole.
- 11. (Original) The method of claim 1, further comprising administering to the subject an amount of one or more non-azole compounds effective to treat the non-fungal induced mucositis of the distal intestinal tract.
- 12. (Original) The method of claim 11, wherein the non-azole compounds are selected from a list consisting of anti-inflammatory or anti-bacterial compounds.

13-44. (Cancelled)